Most Surveyed Clinicians Will Prescribe Amgen/GlaxoSmithKline's Prolia as Either a Second- or Third-Line Therapy for Osteoporosis

Thursday, December 3, 2009 General News
Email Print This Page Comment
Font : A-A+

More Than Half of Surveyed MCOs Will Place Prolia, Pfizer's Viviant and Pfizer/Ligand Pharmaceuticals' Aprela on Tier 3 or Higher in Their Formularies, According to a New Report from Decision Resources

For more information, contact:

Decision Resources

Decision Resources, Inc.

Christopher Comfort

Elizabeth Marshall

781-296-2597

781-296-2563

ccomfort@dresources.com

emarshall@dresources.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook